Next Article in Journal
Early Immunological Effects of Ischemia-Reperfusion Injury: No Modulation by Ischemic Preconditioning in a Randomised Crossover Trial in Healthy Humans
Next Article in Special Issue
Exosomes-Associated DNA—New Marker in Pregnancy Complications?
Previous Article in Journal
Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases
Open AccessReview

Why the Gold Standard Approach by Mammography Demands Extension by Multiomics? Application of Liquid Biopsy miRNA Profiles to Breast Cancer Disease Management

1
Department of Obstetrics and Gynaecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin University Hospital, 03659 Martin, Slovak Republic
2
Division of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, 03601 Martin, Slovak Republic
3
Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 03601 Martin, Slovak Republic
4
Department of Pathology, St. Elizabeth Cancer Institute Hospital, 81250 Bratislava, Slovak Republic
5
Biomedical Research Centre, Slovak Academy of Sciences, 81439 Bratislava, Slovak Republic
6
Center for Cancer Prevention, 03659 Martin, Slovak Republic
7
Department of Radiology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 03659 Martin, Slovak Republic
8
Department of Obstetrics and Gynaecology, Kukuras Michalovce Hospital, 07101 Michalovce, Slovak Republic
9
Oncogynecology Unit, Penta Hospitals International, Svet Zdravia, Michalovce 07101, Slovak Republic
10
Weill Cornell Medicine in Qatar, Qatar Foundation-Education City, Doha 24144, Qatar
11
Department of Thoracic Surgery, Faculty of Medicine and Dentistry, Medical University of Silesia, 40055 Katowice, Poland
12
Centre of Obstetrics, Gynaecology and Gynaecologic Oncology, DonauIsar Klinikum Deggendorf-Dingolfing-Landau, 94469 Deggendorf, Germany
13
Radiological Hospital, Rheinische Friedrich-Wilhelms-University of Bonn, 53105 Bonn, Germany
14
Breast Cancer Research Centre, Rheinische Friedrich-Wilhelms-University of Bonn, 53105 Bonn, Germany
15
Centre for Integrated Oncology, Cologne-Bonn, Rheinische Friedrich-Wilhelms-University of Bonn, 53105 Bonn, Germany
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2019, 20(12), 2878; https://doi.org/10.3390/ijms20122878
Received: 17 April 2019 / Revised: 7 June 2019 / Accepted: 11 June 2019 / Published: 13 June 2019
(This article belongs to the Special Issue Cell-Free Nucleic Acids)
In the global context, the epidemic of breast cancer (BC) is evident for the early 21st century. Evidence shows that national mammography screening programs have sufficiently reduced BC related mortality. Therefore, the great utility of the mammography-based screening is not an issue. However, both false positive and false negative BC diagnosis, excessive biopsies, and irradiation linked to mammography application, as well as sub-optimal mammography-based screening, such as in the case of high-dense breast tissue in young females, altogether increase awareness among the experts regarding the limitations of mammography-based screening. Severe concerns regarding the mammography as the “golden standard” approach demanding complementary tools to cover the evident deficits led the authors to present innovative strategies, which would sufficiently improve the quality of the BC management and services to the patient. Contextually, this article provides insights into mammography deficits and current clinical data demonstrating the great potential of non-invasive diagnostic tools utilizing circulating miRNA profiles as an adjunct to conventional mammography for the population screening and personalization of BC management. View Full-Text
Keywords: breast cancer; screening; liquid biopsy; omics; multi-level diagnostics; individualized patient profile; miRNA; mammography; predictive and preventive approach; personalized medicine breast cancer; screening; liquid biopsy; omics; multi-level diagnostics; individualized patient profile; miRNA; mammography; predictive and preventive approach; personalized medicine
Show Figures

Figure 1

MDPI and ACS Style

Zubor, P.; Kubatka, P.; Kajo, K.; Dankova, Z.; Polacek, H.; Bielik, T.; Kudela, E.; Samec, M.; Liskova, A.; Vlcakova, D.; Kulkovska, T.; Stastny, I.; Holubekova, V.; Bujnak, J.; Laucekova, Z.; Büsselberg, D.; Adamek, M.; Kuhn, W.; Danko, J.; Golubnitschaja, O. Why the Gold Standard Approach by Mammography Demands Extension by Multiomics? Application of Liquid Biopsy miRNA Profiles to Breast Cancer Disease Management. Int. J. Mol. Sci. 2019, 20, 2878.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop